Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility.

Farrukee R, Zarebski AE, McCaw JM, Bloom JD, Reading PC, Hurt AC.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01081-18. doi: 10.1128/AAC.01081-18. Print 2018 Nov.

2.

Selection of multi-drug resistant influenza A and B viruses under zanamivir pressure and their replication fitness in ferrets.

Oh DY, Panozzo J, Vitesnik S, Farrukee R, Piedrafita D, Mosse J, Hurt AC.

Antivir Ther. 2018;23(4):295-306. doi: 10.3851/IMP3135.

PMID:
28195559
3.

DC-SIGN and L-SIGN Are Attachment Factors That Promote Infection of Target Cells by Human Metapneumovirus in the Presence or Absence of Cellular Glycosaminoglycans.

Gillespie L, Gerstenberg K, Ana-Sosa-Batiz F, Parsons MS, Farrukee R, Krabbe M, Spann K, Brooks AG, Londrigan SL, Reading PC.

J Virol. 2016 Aug 12;90(17):7848-63. doi: 10.1128/JVI.00537-16. Print 2016 Sep 1.

4.

Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility.

Farrukee R, Leang SK, Butler J, Lee RT, Maurer-Stroh S, Tilmanis D, Sullivan S, Mosse J, Barr IG, Hurt AC.

J Antimicrob Chemother. 2015 Jul;70(7):2004-12. doi: 10.1093/jac/dkv065. Epub 2015 Mar 18.

PMID:
25786478
5.

Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses.

Farrukee R, Mosse J, Hurt AC.

Expert Rev Anti Infect Ther. 2013 Nov;11(11):1135-45. doi: 10.1586/14787210.2013.842466. Epub 2013 Oct 7. Review.

PMID:
24093683

Supplemental Content

Loading ...
Support Center